[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100565775":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":138,"collaborators":140,"id":144,"slug":145,"hasResults":146,"nctId":147,"briefTitle":148,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":146,"sex":151,"minAge":152,"maxAge":20,"enrollmentInfo":153,"targetDuration":20,"studyType":156,"phases":157,"briefSummary":159,"conditions":160,"keywords":20,"overallStatus":92,"whyStopped":20,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":171},{"fullName":5,"class":6},"Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"CAB LA + RPV LA","EXPERIMENTAL","the proportion of participants ≥60 years on stable oral ART that switch to CAB LA + RPV LA with plasma HIV-1 RNA ≥50 copies\u002FmL at month 12 in the intention-to- treat exposed (ITT-E) population",[13],"Drug: Cabotegravir LA + Rilpivirine LA",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Cabotegravir LA + Rilpivirine LA","Cabotegravir (CAB) LA 600mg and Rilpivirine (RPV) LA 900mg will be administered intramuscularly every 2 months after an induction phase with a single administration in months 1 and 2.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Enrique Bernal Morell Jefe de Servicio de Medicina Interna. Hospital General Univer, MD","CONTACT","968 35 90 00","ebm.hgurs@gmail.com",[28,47,61,76,90,102,113,124],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Hospital General Universitario de Elche","NOT_YET_RECRUITING","Elche","Alicante","03203","Spain","ES",{"type":37,"coordinates":38},"Point",[39,40],-0.70107,38.26218,{"lat":40,"lon":39},[43],{"name":44,"role":24,"phone":45,"phoneExt":20,"email":46},"Mar Masiá Canuto, MD","966 61 69 00","marmasiac@gmail.com",{"facility":48,"status":30,"city":49,"state":32,"zip":50,"country":34,"countryCode":35,"cosmosGeoPoint":51,"geoPoint":55,"contacts":56},"Hospital Marina Baixa","Villajoyosa","03570",{"type":37,"coordinates":52},[53,54],-0.23346,38.50754,{"lat":54,"lon":53},[57],{"name":58,"role":24,"phone":59,"phoneExt":20,"email":60},"María Inmaculada Concepción Amador, MD","966 90 72 00","concha.amador@gmail.com",{"facility":62,"status":30,"city":63,"state":64,"zip":65,"country":34,"countryCode":35,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"Hospital General Universitario Santa Lucía","Cartagena","Murcia","30202",{"type":37,"coordinates":67},[68,69],-0.98397,37.60197,{"lat":69,"lon":68},[72],{"name":73,"role":24,"phone":74,"phoneExt":20,"email":75},"Francisco Jesús Vera Méndez, MD","968 12 86 00","franciscovera72@gmail.com",{"facility":77,"status":30,"city":78,"state":64,"zip":79,"country":34,"countryCode":35,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"Hospital Universitario Rafael Mendéz de Lorca","Lorca","30813",{"type":37,"coordinates":81},[82,83],-1.7017,37.67119,{"lat":83,"lon":82},[86],{"name":87,"role":24,"phone":88,"phoneExt":20,"email":89},"Ana Isabel Peláez Ballesta, MD","968 44 55 00","anapelaezballesta@gmail.com",{"facility":91,"status":92,"city":64,"state":64,"zip":93,"country":34,"countryCode":35,"cosmosGeoPoint":94,"geoPoint":98,"contacts":99},"Hospital General Universitario Reina Sofia","RECRUITING","30003",{"type":37,"coordinates":95},[96,97],-1.13004,37.98704,{"lat":97,"lon":96},[100],{"name":101,"role":24,"phone":20,"phoneExt":25,"email":26},"Enrique Bernal Morel, MD",{"facility":103,"status":30,"city":64,"state":64,"zip":104,"country":34,"countryCode":35,"cosmosGeoPoint":105,"geoPoint":107,"contacts":108},"Hospital General Universitario Morales Meseguer","30008",{"type":37,"coordinates":106},[96,97],{"lat":97,"lon":96},[109],{"name":110,"role":24,"phone":111,"phoneExt":20,"email":112},"Joaquín Bravo Urbieta, MD","968 36 09 00","jokinbravo@hotmail.com",{"facility":114,"status":30,"city":64,"state":64,"zip":115,"country":34,"countryCode":35,"cosmosGeoPoint":116,"geoPoint":118,"contacts":119},"Hospital Clinico Universitario Virgen de la Arrixaca Murcia","30100",{"type":37,"coordinates":117},[96,97],{"lat":97,"lon":96},[120],{"name":121,"role":24,"phone":122,"phoneExt":20,"email":123},"Carlos Galera, MD","968369500","carlosgalerap@gmail.com",{"facility":125,"status":30,"city":126,"state":64,"zip":127,"country":34,"countryCode":35,"cosmosGeoPoint":128,"geoPoint":132,"contacts":133},"Hospital General Universitario Los Arcos del Mar Menor","Pozo-Aledo","30739",{"type":37,"coordinates":129},[130,131],-0.8573,37.8077,{"lat":131,"lon":130},[134],{"name":135,"role":24,"phone":136,"phoneExt":20,"email":137},"Diana Piñar Cabezos, MD","968 56 50 00","dianapinar@hotmail.com",{"type":139,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[141],{"name":142,"class":143},"ViiV Healthcare","INDUSTRY","100565775","phase-4-long-acting-cabotegravir-plus-rilpivirine-in-people-living-with-hiv-1-aged--60-years-for-24-months-100565775",false,"NCT06646562","Long Acting Cabotegravir Plus Rilpivirine in People Living with HIV-1 Aged ≥ 60 Years for 24 Months.","LOVER60","Inclusion Criteria:\n\n* Be able to understand and comply with protocol requirements, instructions, and restrictions.\n* Understand the long-term commitment to the study and be likely to complete the study as planned.\n* Be considered appropriate candidates for participation in an investigative clinical trial with oral and intramuscularly injectable medications (e.g., no active substance use disorder, acute major organ disease, or planned long-term work assignments out of the country, etc.).\n* Must be on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class.\n* Plasma HIV-1 RNA \\\u003C50 copies\u002FmL at screening.\n* A female subject is eligible to participate if she is not pregnant (as confirmed by a negative serum hCG test at screen and a negative urine hCG test at randomization) and not lactating\n\nExclusion Criteria:\n\n* Plasma HIV-1 RNA measurement ≥50 copies\u002FmL within 6 months prior to screening. Blips are allowed (increased viral load ≥50 copies\u002FmL but \\\u003C200 copies\u002FmL preceded and followed by a viral load less than 50 copies\u002FmL)\n* Any drug holiday during the window between initiating first HIV ART and 6 months prior to screening, except for brief periods (less than 1 month) where all ART was stopped due to tolerability and\u002For safety concerns.\n* Any switch to a second line regimen, defined as change of a single drug or multiple drugs simultaneously, due to virologic failure to NNRTI or INSTI (defined as a confirmed plasma HIV-1 RNA measurement ≥200 copies\u002FmL after initial suppression to \\\u003C50 copies\u002FmL while on first line HIV therapy regimen)\n* Subjects who are currently participating in or anticipate being selected for any other interventional study. Observational studies and intervention studies that do not include treatments are allowed unless they interfere with scheduled visits.\n* Participants receiving any prohibited medication and who are unwilling or unable to switch to an alternative medication","ALL","60 Years",{"count":154,"type":155},120,"ESTIMATED","INTERVENTIONAL",[158],"PHASE4","People Living with HIV-1 (PLHIV) are an important group of patients attending their specialist's and continue growing thanks to efficacy antiretroviral treatment (ART), allowing them to stabilize the HIV-infection and to live a normal life despite the infection. The present study is encouraged to demonstrate that efficacy and security of CAB LA + RPV LA treatment's on this population remains the same compared to younger population of patients. This study also registers some metabolic and hepatic parameters to observe a hypothetical improvement on these parameters, as the population may suffer more comorbidities than younger population and therefore tolerability and convenience gains a huge importance on them. Psychosocial aspects are also very important in these patients as these patients may suffer social stigma, and therefore suffering certain psychological disorders.",[161],"HIV-1 Infected Adults with Controlled Viremia","2025-03-06",{"date":164,"type":165},"2025-03-11","ACTUAL",{"date":167,"type":165},"2025-03-03",{"date":169,"type":155},"2027-01-30",{"name":5,"class":6},8]